Free Trial
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

Arch Therapeutics logo

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.26
52-Week Range
N/A
Volume
N/A
Average Volume
4,068 shs
Market Capitalization
$763,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Stock News Headlines

Shocking discovery could help you target payouts on weekends…
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
Arch Therapeutics, Inc. (ARTH)
Arch Therapeutics Inc ARTH
See More Headlines

ARTH Stock Analysis - Frequently Asked Questions

Arch Therapeutics, Inc. (OTCMKTS:ARTH) issued its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01.

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), Adobe (ADBE), GE Aerospace (GE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
7/23/2020
Today
5/27/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,980,000.00
Net Margins
-8,257.70%
Pretax Margin
-8,257.70%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Price / Cash Flow
N/A
Book Value
($2.43) per share
Price / Book
N/A

Miscellaneous

Free Float
4,529,000
Market Cap
$763,000.00
Optionable
Not Optionable
Beta
4.02

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (OTCMKTS:ARTH) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners